Clovis Oncology Inc. (NASDAQ:CLVS)’s share price shot up 10.9% on Friday . The company traded as high as $17.80 and last traded at $17.12, with a volume of 1,989,384 shares traded. The stock had previously closed at $15.44.

A number of equities analysts have commented on the stock. Vetr downgraded shares of Clovis Oncology from a “buy” rating to a “hold” rating and set a $17.66 target price on the stock. in a research note on Tuesday, June 7th. Credit Suisse Group AG reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Wednesday, June 8th. Mizuho reduced their target price on shares of Clovis Oncology from $21.00 to $15.00 and set a “neutral” rating on the stock in a research note on Monday, April 11th. SunTrust Banks Inc. assumed coverage on shares of Clovis Oncology in a research note on Friday. They set a “buy” rating on the stock. Finally, Zacks Investment Research downgraded shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, April 12th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $29.25.

The firm’s 50-day moving average price is $14.24 and its 200 day moving average price is $16.52. The firm’s market capitalization is $668.28 million.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($2.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.39) by $0.22. During the same quarter last year, the firm earned ($1.86) earnings per share. The company’s quarterly revenue was up NaN% on a year-over-year basis. On average, equities analysts expect that Clovis Oncology Inc. will post ($7.91) EPS for the current fiscal year.

A number of large investors have modified their holdings of the stock. California State Teachers Retirement System boosted its stake in shares of Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock worth $1,806,000 after buying an additional 889 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Clovis Oncology during the fourth quarter worth approximately $3,170,000. Finally, Rhumbline Advisers increased its stake in shares of Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 1,880 shares during the period.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.